Literature DB >> 12746453

Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.

David A Solomon1, Ying Wang, Sejal R Fox, Tah C Lambeck, Sarah Giesting, Zhengdao Lan, Adrian M Senderowicz, Claudio J Conti, Erik S Knudsen.   

Abstract

Cyclin D1 is a proto-oncogene that functions by inactivation of the retinoblastoma tumor suppressor protein, RB. A common polymorphism in the cyclin D1 gene is associated with the production of an alternate transcript of cyclin D1, termed cyclin D1b. Both the polymorphism and the variant transcript are associated with increased risk for multiple cancers and the severity of a given cancer; however, the underlying activities of cyclin D1b have not been elucidated relative to the canonical cyclin D1a. Because cyclin D1b does not possess the threonine 286 phosphorylation site required for nuclear export and regulated degradation, it has been hypothesized to encode a stable nuclear protein that would constitutively inactivate the RB pathway. Surprisingly, we find that cyclin D1b protein does not inappropriately accumulate in cells and exhibits stability comparable to cyclin D1a. As expected, the cyclin D1b protein was constitutively localized in the nucleus, whereas cyclin D1a was exported to the cytoplasm in S-phase. Despite enhanced nuclear localization, we find that cyclin D1b is a poor catalyst of RB phosphorylation/inactivation. However, cyclin D1b potently induced cellular transformation in contrast to cyclin D1a. In summary, we demonstrate that cyclin D1b specifically disrupts contact inhibition in a manner distinct from cyclin D1a. These data reveal novel roles for d-type cyclins in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746453     DOI: 10.1074/jbc.M303969200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  92 in total

1.  Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.

Authors:  Vandana Gupta Abramson; Andrea B Troxel; Michael Feldman; Carolyn Mies; Yan Wang; Lauren Sherman; Sara McNally; Alan Diehl; Angela Demichele
Journal:  Anticancer Res       Date:  2010-04       Impact factor: 2.480

2.  Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma.

Authors:  Teresa Warchoł; Lukasz Kruszyna; Margarita Lianeri; Andrzej Roszak; Paweł P Jagodziński
Journal:  Pathol Oncol Res       Date:  2010-08-03       Impact factor: 3.201

3.  The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines.

Authors:  John P Alao; Simon C Gamble; Alexandra V Stavropoulou; Karen M Pomeranz; Eric W-F Lam; R Charles Coombes; David M Vigushin
Journal:  Mol Cancer       Date:  2006-02-17       Impact factor: 27.401

4.  Cyclin D1 overexpression increases susceptibility to 4-nitroquinoline-1-oxide-induced dysplasia and neoplasia in murine squamous oral epithelium.

Authors:  Jonathan F Wilkey; Glenn Buchberger; Kirsten Saucier; Salony M Patel; Ellen Eisenberg; Hiroshi Nakagawa; Carmen Z Michaylira; Anil K Rustgi; Sanjay M Mallya
Journal:  Mol Carcinog       Date:  2009-09       Impact factor: 4.784

Review 5.  Altered RNA Processing in Cancer Pathogenesis and Therapy.

Authors:  Esther A Obeng; Connor Stewart; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2019-10-14       Impact factor: 39.397

6.  CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis.

Authors:  Jing Ni; Meilin Wang; Miaomiao Wang; Shilong Fu; Delan Zhou; Zhengdong Zhang; Suping Han
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-15       Impact factor: 4.553

Review 7.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

Review 8.  In the wrong place at the wrong time: does cyclin mislocalization drive oncogenic transformation?

Authors:  Jonathan D Moore
Journal:  Nat Rev Cancer       Date:  2013-02-07       Impact factor: 60.716

Review 9.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

10.  Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Authors:  Michael A Augello; Craig J Burd; Ruth Birbe; Christopher McNair; Adam Ertel; Michael S Magee; Daniel E Frigo; Kari Wilder-Romans; Mark Shilkrut; Sumin Han; Danielle L Jernigan; Jeffry L Dean; Alessandro Fatatis; Donald P McDonnell; Tapio Visakorpi; Felix Y Feng; Karen E Knudsen
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.